BiotechTube

ABBV-47D11 + Placebo for ABBV-47D11 + ABBV-2B04 + Placebo for ABBV-2B04

Phase 1Completed
0 watching 0 views this week💤 Quiet
33
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

CoronaVirus Disease-2019 (COVID-19)

Conditions

CoronaVirus Disease-2019 (COVID-19)

Trial Timeline

Dec 10, 2020 → Aug 24, 2021

NCT ID
NCT04644120

About ABBV-47D11 + Placebo for ABBV-47D11 + ABBV-2B04 + Placebo for ABBV-2B04

ABBV-47D11 + Placebo for ABBV-47D11 + ABBV-2B04 + Placebo for ABBV-2B04 is a phase 1 stage product being developed by AbbVie for CoronaVirus Disease-2019 (COVID-19). The current trial status is completed. This product is registered under clinical trial identifier NCT04644120. Target conditions include CoronaVirus Disease-2019 (COVID-19).

Hype Score Breakdown

Clinical
10
Activity
5
Company
10
Novelty
3
Community
2

Clinical Trials (1)

NCT IDPhaseStatus
NCT04644120Phase 1Completed

Competing Products

20 competing products in CoronaVirus Disease-2019 (COVID-19)

See all competitors
ProductCompanyStageHype Score
Isavuconazonium Injection [Cresemba] + PlaceboAstellas PharmaPhase 3
77
bamlanivimab 7000mg + BRII-196+BRII-198 + AZD7442 (IV) + AZD7442 (IM) + SNG001 + Camostat + BMS-986414 + BMS-986413 + SAB-185 (3,840 Units/kg) + SAB-185 (10,240 Units/kg) + CASIRIVIMAB + IMDEVIMAB + Placebo for Bamlanivimab 7000mg + Placebo for Bamlanivimab 700mg + Placebo for BRII-196+BRII-198 + Placebo for SNG001 + Placebo for Camostat + Placebo for SAB-185 (low dose) + Placebo for BMS-986414 + BMS-986413 + Placebo for AZD7442 (IV) + Placebo for AZD7442 (IM) + Placebo for SAB-185 (high dose) + bamlanivimab 700mgEli LillyPhase 2/3
65
EQ001 + EQ001 PlaceboBioconPhase 3
77
Mesenchymal stem cellRohto PharmaceuticalPhase 1
33
Ibrutinib + PlaceboAbbViePhase 2
52
600 mg AZD7442 IV + 600mg placebo IVAstraZenecaPhase 2
52
EVUSHELDAstraZenecaPre-clinical
23
AZD7442 (tixagevimab [AZD8895] + cilgavimab [AZD1061]) + AZD7442 (tixagevimab [AZD8895] + cilgavimab [AZD1061])AstraZenecaPhase 2
52
AZD7442 IM + Placebo IM + AZD7442 IM + Placebo IM + AZD7442 IV + Placebo IV + AZD7442 IV + Placebo IVAstraZenecaPhase 1
33
Molnupiravir + PlaceboMerckPhase 3
77
Molnupiravir + PlaceboMerckPhase 2/3
65
V590MerckPhase 1
33
Molnupiravir + PlaceboMerckPhase 2/3
65
V591MerckPhase 1/2
41
Efprezimod alfa + PlaceboMerckPhase 3
77
M5049 + M5049 + PlaceboMerckPhase 2
52
Molnupiravir + PlaceboMerckPhase 3
77
Frespaciguat + PlaceboMerckPhase 1
33
Canakinumab + PlaceboNovartisPhase 3
77
Ruxolitinib + FostamatinibNovartisPhase 1/2
41

Other Products from AbbVie

Pancrelipase + PancrelipaseApproved
85
CREONApproved
85
Venetoclax + AzacitidineApproved
85
Oxybutynin + PlaceboApproved
85
Glecaprevir-pibrentasvirApproved
85